Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8382519 | 0.94 | HSD11B1 (0.33) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL30789930 | 0.84 | HSD11B1 (0.35) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL8481807 | 0.84 | HSD11B1 (0.35) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL3517535 | 0.81 | HTR2A (0.37) | HPGDHSD11B1 | |
| SCHEMBL3518657 | 0.75 | MEN1 (0.37) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL8377336 | 0.74 | SLC6A4 (0.38) | HPGDHSD11B1 | |
| SCHEMBL6994885 | 0.71 | IDO1 (0.50) | — | |
| Benzaldehyde SCHEMBL5716511 | 0.70 | ALDH1A1 (0.45) | ALDH1A1MEN1GAAKMT2AKDM4E | |
| SCHEMBL3359792 | 0.70 | PDE4B (0.49) | ALDH1A1HPGDKDM4EPDE4B | |
| SCHEMBL5863923 | 0.69 | PDE4B (0.47) | ALDH1A1HPGDKDM4EPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959959-B1 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | PROKR2, PROKR1, NTSR2 | ALDH1A1 4629/4885MEN1 410/4885GAA 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.